PTC Therapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
PTC Therapeutics Stock Forecast and Price Target
The average price target for PTC Therapeutics's stock set by recognized analysts recently is $29.50, which would result in a potential downside of approximately -12.25% if it reached this mark. The estimation is based on a high estimate of $45.00 and a low estimate of $16.00. If you are interested in PTCT stock, you should also look at its competitors.
-12.25% Downside
PTC Therapeutics Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, PTC Therapeutics's Price has grown, moving from $0.00 to $0.00 – an increase of 100.00%. In the next year, analysts predict that Fair Value will jump to $36.11 – up 100.00% from the current level. Looking ahead to nine years, experts forecast that Fair Value will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$160.81 | Buy/Sell | $178.42 | 15.04% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$278.39 | Buy/Sell | $303.65 | 14.77% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$65.33 | Buy/Sell | $87.82 | 22.46% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$213.51 | Buy/Sell | $299.62 | 35.12% |
PTC Therapeutics Revenue Forecast for 2023 - 2025 - 2030
In the last three years, PTC Therapeutics's Revenue has grown, moving from $380.77M to $937.82M – an increase of 146.30%. The next year, 13 experts forecast that PTC Therapeutics's Revenue will decrease by 31.06%, reaching $646.55M. Looking ahead to nine years, experts forecast that Revenue will grow by 27.37%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$83.80 | Buy/Sell | $111.56 | 31.26% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$53.09 | Buy/Sell | $77.05 | 47.86% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$75.76 | Buy/Sell | $34.00 | 51.80% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$107.00 | Buy/Sell | $85.71 | 2.80% |
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CBAY Stock Forecast | CymaBay Therapeutics | - |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$12.88 | Buy/Sell | $20.42 | 97.98% |
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
PTC Therapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, PTC Therapeutics's EBITDA has fallen from $-300.09M to $-112.81M – a 62.41% decrease. According to 3 prominent analysts, PTC Therapeutics's EBITDA will fall by 18.54% in the next year, reaching $-91.90M. By 2030, professionals believe that PTC Therapeutics's EBITDA will decrease by 173.29%, reaching $82.68M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$10.43 | Buy/Sell | $17.90 | 91.75% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$24.13 | Buy/Sell | $52.00 | 127.93% |
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$17.08 | Buy/Sell | $33.78 | 75.64% |
PTC Therapeutics EBIT Forecast for 2023 - 2025 - 2030
PTC Therapeutics's EBIT has grown in the last three years, jumping from $-343.58M to $-349.40M – an increase of 1.69%. In the following year, 11 experts forecast PTC Therapeutics's EBIT will decrease by 20.38%, to $-278.19M. In 2030, professionals predict that PTC Therapeutics's EBIT will decrease by 229.27%, to $451.68M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$40.86 | Buy/Sell | $63.29 | 88.45% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.88 | Buy/Sell | $42.58 | 14.87% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$34.58 | Buy/Sell | $40.00 | 28.69% |
PTC Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, PTC Therapeutics's EPS has grown, moving from $-5.04 to $0.00 – an increase of 100.00%. In the next year, analysts predict that EPS will jump to $-5.08 – up 100.00% from the current level. Looking ahead to nine years, experts forecast that EPS will grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$6.79 | Buy/Sell | $9.94 | 98.82% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$6.74 | Buy/Sell | $6.00 | 18.69% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.72 | Buy/Sell | $25.00 | 109.04% |
.jpg)